Generic Name: emricasan

Pronunciation: N/A

Abbreviation: N/A

Other Market Name: N/A

Drug Class: NAFLD/NASH Medications

Company: Conatus

Approval Status: Experimental

Generic Version Available: No

Experimental Code: IDN-6556, PF-03491390

General Info

Emricasan (IDN-6556, PF-03491390) is a pan-caspase inhibitor developed by Idun Pharmaceuticals, which was acquired by Pfizer, and most recently acquired by Conatus Pharmaceuticals. Conatus partnered with Novartis in this Phase 2 clinical trial for treatment of non-alcoholic steatohepatitis (NASH).


Dosing Info: N/A

Side Effects


Last Reviewed: February 4, 2019